메뉴 건너뛰기




Volumn 100, Issue 12, 2008, Pages 1417-1424

Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors

Author keywords

Health insurance; HIV AIDS; Treatment

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

EID: 58249111740     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31541-8     Document Type: Article
Times cited : (8)

References (45)
  • 1
    • 0038162585 scopus 로고    scopus 로고
    • Decline in the AIDS and death rates in the EuroSIDA study: An observational study
    • Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
    • (2003) Lancet , vol.362 , pp. 22-29
    • Mocroft, A.1    Ledergerber, B.2    Katlama, C.3
  • 2
    • 2642709177 scopus 로고    scopus 로고
    • Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
    • Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
    • (1998) N Engl J Med , vol.338 , pp. 853-860
    • Palella Jr., F.J.1    Delaney, K.M.2    Moorman, A.C.3
  • 4
    • 33747122666 scopus 로고    scopus 로고
    • Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    • Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843.
    • (2006) JAMA , vol.296 , pp. 827-843
    • Hammer, S.M.1    Saag, M.S.2    Schechter, M.3
  • 5
    • 0037317499 scopus 로고    scopus 로고
    • Non-nucleoside reverse transcriptase inhibitors-an overview. Inf J
    • Bell C, Matthews GV, Nelson MR. Non-nucleoside reverse transcriptase inhibitors-an overview. Inf J SID AIDS. 2003:14:71-77.
    • (2003) SID AIDS , vol.14 , pp. 71-77
    • Bell, C.1    Matthews, G.V.2    Nelson, M.R.3
  • 6
    • 28144452516 scopus 로고    scopus 로고
    • Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
    • Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-721.
    • (2005) Ann Intern Med , vol.143 , pp. 714-721
    • Clifford, D.B.1    Evans, S.2    Yang, Y.3
  • 7
    • 0037192573 scopus 로고    scopus 로고
    • Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort
    • Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS. 2002;16:737-745.
    • (2002) AIDS , vol.16 , pp. 737-745
    • Dieleman, J.P.1    Jambroes, M.2    Gyssens, I.C.3
  • 8
    • 0345256371 scopus 로고    scopus 로고
    • Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort
    • O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407-414.
    • (2003) J Acquir Immune Defic Syndr , vol.34 , pp. 407-414
    • O'Brien, M.E.1    Clark, R.A.2    Besch, C.L.3
  • 9
    • 0242529051 scopus 로고    scopus 로고
    • d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000; 14:499-507.
    • d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000; 14:499-507.
  • 10
    • 0032701801 scopus 로고    scopus 로고
    • Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice
    • Ferrer E. Consiglio E. Podzamczer D, et al. Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice. Scand J Infect Dis. 1999;31:495-499.
    • (1999) Scand J Infect Dis , vol.31 , pp. 495-499
    • Ferrer, E.1    Consiglio, E.2    Podzamczer, D.3
  • 11
    • 0034960836 scopus 로고    scopus 로고
    • Predictors of protease inhibitor- associated adverse events
    • Bonfanti P, Ricci E, Landonio S, et al. Predictors of protease inhibitor- associated adverse events. Biomed Pharmacother. 2001 ;55:321 -323.
    • (2001) Biomed Pharmacother , vol.55 , pp. 321-323
    • Bonfanti, P.1    Ricci, E.2    Landonio, S.3
  • 12
    • 12944265462 scopus 로고    scopus 로고
    • Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000;p23:236-245.
    • Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000;p23:236-245.
  • 13
    • 0141923764 scopus 로고    scopus 로고
    • Murri R, Lepri AC, Phillips AN, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr. 2003;34:184-190.
    • Murri R, Lepri AC, Phillips AN, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr. 2003;34:184-190.
  • 14
    • 3142676567 scopus 로고    scopus 로고
    • Factors associated with efavirenz discontinuation in a large community-based sample of patients
    • Spire B, Carrieri P, Garzot MA, et al. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16:558-564.
    • (2004) AIDS Care , vol.16 , pp. 558-564
    • Spire, B.1    Carrieri, P.2    Garzot, M.A.3
  • 15
    • 3042716048 scopus 로고    scopus 로고
    • The pharmacogenetics of antiretroviral therapy: A review of studies to date
    • Quirk E, McLeod H, Powderiy W. The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin Infect Dis. 2004;39:98-106.
    • (2004) Clin Infect Dis , vol.39 , pp. 98-106
    • Quirk, E.1    McLeod, H.2    Powderiy, W.3
  • 16
    • 19944428456 scopus 로고    scopus 로고
    • Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study
    • Haos DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004:18:2391-2400.
    • (2004) AIDS , vol.18 , pp. 2391-2400
    • Haos, D.W.1    Ribaudo, H.J.2    Kim, R.B.3
  • 17
    • 17644414659 scopus 로고    scopus 로고
    • Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
    • Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005:40:1358-1361.
    • (2005) Clin Infect Dis , vol.40 , pp. 1358-1361
    • Rodriguez-Novoa, S.1    Barreiro, P.2    Rendon, A.3
  • 18
    • 20244364148 scopus 로고    scopus 로고
    • Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
    • Rofger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1-5.
    • (2005) Pharmacogenet Genomics , vol.15 , pp. 1-5
    • Rofger, M.1    Colombo, S.2    Furrer, H.3
  • 19
    • 2942551228 scopus 로고    scopus 로고
    • Homozygous CYP2B6*6 (Ql 72H and K262R) correlates with high plasma efavirenz concentrations in HIV-l patients treated with standard efavirenz-containing regimens
    • Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6*6 (Ql 72H and K262R) correlates with high plasma efavirenz concentrations in HIV-l patients treated with standard efavirenz-containing regimens. Bio- chem Biophys Res Commun. 2004;319:1322-1326.
    • (2004) Bio- chem Biophys Res Commun , vol.319 , pp. 1322-1326
    • Tsuchiya, K.1    Gatanaga, H.2    Tachikawa, N.3
  • 20
    • 0035808574 scopus 로고    scopus 로고
    • Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1- infected patients
    • Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1- infected patients. AIDS. 2001; 15:71-75.
    • (2001) AIDS , vol.15 , pp. 71-75
    • Marzolini, C.1    Telenti, A.2    Decosterd, L.A.3
  • 21
    • 0032727054 scopus 로고    scopus 로고
    • Characterization of the In Vitro Biotransformation of the HIV-l Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450
    • Erickson DA, Mather G, Trager WF, et al. Characterization of the In Vitro Biotransformation of the HIV-l Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450. Drug Mefab Dispos. 1999:27:1488-1495.
    • (1999) Drug Mefab Dispos , vol.27 , pp. 1488-1495
    • Erickson, D.A.1    Mather, G.2    Trager, W.F.3
  • 22
    • 33748328070 scopus 로고    scopus 로고
    • Pharmacogenetics of nevi- rapine-associated hepatotoxicity: An Adult AIDS Clinical Trials Group collaboration
    • Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevi- rapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43:783-786.
    • (2006) Clin Infect Dis , vol.43 , pp. 783-786
    • Haas, D.W.1    Bartlett, J.A.2    Andersen, J.W.3
  • 23
    • 33748288115 scopus 로고    scopus 로고
    • Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity
    • Ritchie MD, Haas DW, Motsinger AA, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis. 2006;43:779-782.
    • (2006) Clin Infect Dis , vol.43 , pp. 779-782
    • Ritchie, M.D.1    Haas, D.W.2    Motsinger, A.A.3
  • 24
    • 85031348215 scopus 로고    scopus 로고
    • Moore RD, Keruly J, Gebo KA, et al. Racial Differences in Efavirenz Discontinuation in Clinical Practice. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005. Boston, MA.
    • Moore RD, Keruly J, Gebo KA, et al. Racial Differences in Efavirenz Discontinuation in Clinical Practice. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005. Boston, MA.
  • 25
    • 10044283687 scopus 로고    scopus 로고
    • Racial differences in clinical efficacy of efavirenz-based antiretroviral therapy
    • Paper presented at: February 24-28, Seattle, WA
    • Wegner S, Vahey M, Dolan M, et al. Racial differences in clinical efficacy of efavirenz-based antiretroviral therapy. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002. Seattle, WA.
    • (2002) 9th Conference on Retroviruses and Opportunistic Infections
    • Wegner, S.1    Vahey, M.2    Dolan, M.3
  • 27
    • 33747102040 scopus 로고    scopus 로고
    • Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-l Infection: A Randomized Controlled Trial
    • Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-l Infection: A Randomized Controlled Trial. JAMA. 2006:296:769-781.
    • (2006) JAMA , vol.296 , pp. 769-781
    • Gulick, R.M.1    Ribaudo, H.J.2    Shikuma, C.M.3
  • 28
    • 36549085175 scopus 로고    scopus 로고
    • Racial differences in virologic failure associated with adherence and quality of life on efavirenz- containing regimens for initial HIV therapy: Results of ACTG A5095
    • Schackman BR, Ribaudo HJ, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on efavirenz- containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007;46:547-554.
    • (2007) J Acquir Immune Defic Syndr , vol.46 , pp. 547-554
    • Schackman, B.R.1    Ribaudo, H.J.2    Krambrink, A.3
  • 29
    • 0036156409 scopus 로고    scopus 로고
    • Pharmacokinetic variability caused by gender: Do women have higher indinavir exposure than men?
    • Burger DM, Siebers MC, Hugen PW, et al. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr. 2002;29:101-102.
    • (2002) J Acquir Immune Defic Syndr , vol.29 , pp. 101-102
    • Burger, D.M.1    Siebers, M.C.2    Hugen, P.W.3
  • 30
    • 2342563028 scopus 로고    scopus 로고
    • Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1
    • Pai MP, Schriever CA, Diaz-Linares M. et al. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy. 2004;24:592-599.
    • (2004) Pharmacotherapy , vol.24 , pp. 592-599
    • Pai, M.P.1    Schriever, C.A.2    Diaz-Linares, M.3
  • 31
    • 7244243920 scopus 로고    scopus 로고
    • Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
    • Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4256-4262.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 4256-4262
    • Ribera, E.1    Lopez, R.M.2    Diaz, M.3
  • 32
    • 0742304500 scopus 로고    scopus 로고
    • Sex differences in nevirapine disposition in HIV-infected patients
    • Regazzi M, Villani P, Seminari E, et al. Sex differences in nevirapine disposition in HIV-infected patients. AIDS. 2003;17:2399-2400.
    • (2003) AIDS , vol.17 , pp. 2399-2400
    • Regazzi, M.1    Villani, P.2    Seminari, E.3
  • 33
    • 4043062089 scopus 로고    scopus 로고
    • No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors
    • Dailly E, Billaud E, Reliquet V, et al. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol. 2004;60:343-348.
    • (2004) Eur J Clin Pharmacol , vol.60 , pp. 343-348
    • Dailly, E.1    Billaud, E.2    Reliquet, V.3
  • 34
    • 0036421181 scopus 로고    scopus 로고
    • Hepatotoxicity following nevirapine-containing regimens in HIV-l-infected individuals
    • De Maat MM, Mathot RA, Veldkamp Al, et al. Hepatotoxicity following nevirapine-containing regimens in HIV-l-infected individuals. Pharmacol Res. 2002:46:295-300.
    • (2002) Pharmacol Res , vol.46 , pp. 295-300
    • De Maat, M.M.1    Mathot, R.A.2    Veldkamp, A.3
  • 35
    • 14744297565 scopus 로고    scopus 로고
    • Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study
    • Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38:320-328.
    • (2005) J Acquir Immune Defic Syndr , vol.38 , pp. 320-328
    • Li, X.1    Margolick, J.B.2    Conover, C.S.3
  • 36
    • 0025690750 scopus 로고
    • Use of automated databases for pharmacoepidemiology research
    • Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev. 1990;12:87-107.
    • (1990) Epidemiol Rev , vol.12 , pp. 87-107
    • Strom, B.L.1    Carson, J.L.2
  • 37
    • 0017274715 scopus 로고
    • Medicaid records as a valid data source: The Tennessee experience
    • Federspiel CF, Ray WA, Schaffner W. Medicaid records as a valid data source: the Tennessee experience. Med Care. 1976; 14:166-172.
    • (1976) Med Care , vol.14 , pp. 166-172
    • Federspiel, C.F.1    Ray, W.A.2    Schaffner, W.3
  • 38
    • 0028800261 scopus 로고
    • Recall accuracy for prescription medications: Self-report compared with database information
    • West SL, Savitz DA, Koch G, et al. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995,142:1103-1112.
    • (1995) Am J Epidemiol , vol.142 , pp. 1103-1112
    • West, S.L.1    Savitz, D.A.2    Koch, G.3
  • 39
    • 20744442305 scopus 로고    scopus 로고
    • Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: Results from a cohort of 416 multi-experienced HIV-infected individuals
    • Bongiovanni M, Cicconi P, Landonio S, et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents. 2005;26:88-91.
    • (2005) Int J Antimicrob Agents , vol.26 , pp. 88-91
    • Bongiovanni, M.1    Cicconi, P.2    Landonio, S.3
  • 40
    • 0023680423 scopus 로고
    • Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons
    • Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988:109:359-363.
    • (1988) Ann Intern Med , vol.109 , pp. 359-363
    • Griffin, M.R.1    Ray, W.A.2    Schaffner, W.3
  • 41
    • 19244365446 scopus 로고    scopus 로고
    • Oral erythromycin and the risk of sudden death from cardiac causes
    • Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-1096.
    • (2004) N Engl J Med , vol.351 , pp. 1089-1096
    • Ray, W.A.1    Murray, K.T.2    Meredith, S.3
  • 42
    • 0037027050 scopus 로고    scopus 로고
    • COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
    • Ray WA, Stein CM, Dougherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
    • (2002) Lancet , vol.360 , pp. 1071-1073
    • Ray, W.A.1    Stein, C.M.2    Dougherty, J.R.3
  • 43
    • 14744291275 scopus 로고    scopus 로고
    • Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons
    • Hulgan T, Sterling TR, Daugherty J, et al. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr. 2005;38:277-282.
    • (2005) J Acquir Immune Defic Syndr , vol.38 , pp. 277-282
    • Hulgan, T.1    Sterling, T.R.2    Daugherty, J.3
  • 44
    • 85031360889 scopus 로고    scopus 로고
    • Bailey J, Jenkins PH, Arheart KL, et al. The Impact of the Ryan White CARE Act on Quality and Outcomes of HIV/AIDS Care in Tennesee's TennCare System 1998-2000: Infectious Diseases Society of America; 2003.
    • Bailey J, Jenkins PH, Arheart KL, et al. The Impact of the Ryan White CARE Act on Quality and Outcomes of HIV/AIDS Care in Tennesee's TennCare System 1998-2000: Infectious Diseases Society of America; 2003.
  • 45
    • 0141955990 scopus 로고    scopus 로고
    • Improvements in access to care for HIV and AIDS in a statewide Medicaid managed care system
    • Bailey JE, Van Brunt DL, Raffanti SP, et al. Improvements in access to care for HIV and AIDS in a statewide Medicaid managed care system. Am J Manag Care. 2003;9:595-602.
    • (2003) Am J Manag Care , vol.9 , pp. 595-602
    • Bailey, J.E.1    Van Brunt, D.L.2    Raffanti, S.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.